Veterinary Vaccines Patents: Who Leads, Where the Gaps Are 2026
- Filing activity peaked in 2023 at 21 families then eased back toward the 2022 midpoint of 6, a pattern more consistent with a plateau than sustained growth.
- China leads receiving offices with 31 filings ahead of the EPO (20), WIPO/PCT (14) and the United States (13), showing the filing centre of gravity has shifted east of where most cited prior art originates.
- Adjuvant and cytokine-adjuvant claims dominate citations with interleukin-12 adjuvant filings appearing twice among the five most-cited records, anchoring a narrow but heavily fenced sub-area.
What this landscape covers
Veterinary vaccine and animal biologics patents in this dataset are filtered for claims touching adjuvant formulation, mass administration, cold-chain stability, cross-protection and DIVA (differentiating infected from vaccinated animals) capability — features that separate a lab-stage antigen from a field-deployable product. The IPC mix is heavily weighted to A61K (medicinal preparations) and A61P (therapeutic activity), with a smaller but persistent presence of C07K peptide/protein and C12N microorganism/genetic-engineering claims that point to subunit and vector-based approaches sitting alongside classic inactivated and live-attenuated formulations.
Coverage runs from 2015 through the 2026-07-31 cut-off, drawing on 114 published patent families. Publication typically lags filing by roughly 18 months, so 2025 and 2026 counts are understated and should not be read as a real decline yet.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
The trend line and the IPC breakdown together show a field that built up filing volume through the early 2020s and has since flattened, concentrated overwhelmingly in a small set of therapeutic and preparation subclasses.
A plateau after a 2023 peak
Filings rose from 4 in 2017 to a peak of 21 in 2023, but the 2022 midpoint of 6 and the drop-off into 2025-2026 (partial year) suggest the growth phase has already passed its steepest point, with publication lag accounting for some but not all of the recent-year softness.
Concentrated in two subclasses, thin everywhere else
A61K (113 of 114 records) and A61P (77) cover nearly every filing, while C07K, C12N, C12P, C08B, C12R and B82Y each appear in single digits to low double digits — evidence that formulation and therapeutic-use claims are the dense ground, and genetic-engineering, fermentation and nanoparticle-delivery claims remain comparatively open.
Shares are the percentage of the 114 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Veterinary Vaccines and Biologics with Eureka
This page is one run against one query. Ask Eureka your own question about veterinary vaccines and biologics and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records set the boundaries
Interleukin-12 as a veterinary vaccine adjuvant (US20080003201A1, Wyeth)
This disclosure describes a composition for enhancing the immunogenicity of a veterinary vaccine that comprises a pharmacologically effective amount of an immunomodulator and an immunoadjuvant. Additionally, the disclosure describes a vaccine composition comprising an effective immunizing amount of an antigen, an immunomodulator, an immunoadjuvant and a pharmaceutically acceptable carrier. The compositions may optionally contain conventional, secondary adjuvants or preservatives. The disclosure further describes a unique method for enhancing or accelerating the immunogenicity of weak, immunosuppressive or marginally safe antigens by administering to an avian or mammalian species a pharmacologically effective amount of the composition.Filed by Wyeth, published 2008-01-03; the interleukin-12 adjuvant concept it describes recurs among this dataset's most-cited records under related filing numbers.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US4567042A | Inactivated canine coronavirus vaccine | 69 |
| 2 | WO2013030608A1 | Nanoparticle-based veterinary vaccine | 27 |
| 3 | WO2003024354A2 | Interleukin-12 as a veterinary vaccine adjuvant | 23 |
| 4 | WO2012092226A1 | Veterinary vaccine composition against infections caused by salmonella | 21 |
| 5 | US20030129161A1 | Interleukin-12 as a veterinary vaccine adjuvant | 21 |
| 6 | EP1136077A1 | Preparations containing virus-like particles as immunopotentiators administered through the mucosa | 19 |
| 7 | WO1988001176A1 | Regulating animal reproduction | 15 |
| 8 | EP0329264A2 | Veterinary vaccines | 14 |
| 9 | CN109806391A | 一种兽用疫苗免疫水溶性复合佐剂的制备方法及其应用 | 13 |
| 10 | CN101757619A | 兽用狂犬病灭活疫苗及其制备方法 | 9 |
Ranked by citation count within this corpus; older records accumulate citations simply by being available longer, so treat this as a map of influence rather than current commercial relevance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once family counts, receiving offices and citation concentration are read together: where claim density sits, where the growth actually happened, and where the influential prior art still sits unchallenged.
China now files more than double the US volume
With 31 records at the Chinese office against 13 at the USPTO, 20 at the EPO and 14 via PCT, the jurisdictional weight of new veterinary biologics claims has moved toward China even though the most-cited foundational patents originate from Western filers.
Formulation claims are almost universal, differentiation is not
Nearly every record touches A61K medicinal-preparation claims, meaning novelty in this field is rarely about the fact of a formulation existing and almost always about the specific adjuvant, delivery vehicle or stabilisation method layered on top.
The filing curve has already crested
Activity roughly tripled from the 2022 midpoint to the 2023 peak before easing off; combined with publication lag, this points to a field that consolidated fast rather than one still accelerating.
Cytokine-adjuvant claims anchor the influential prior art
Interleukin-12 adjuvant filings appear twice among the five most-cited records in this corpus, alongside an inactivated canine coronavirus vaccine and nanoparticle- and Salmonella-targeted compositions, marking the adjuvant mechanism itself as the most heavily cited claim territory.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to veterinary vaccines and biologics, with the prior art for and against each one.
Who holds ground, and who has gone quiet
Assignee activity in this dataset is a mix of established animal-health names and research institutes, several of which show no filings in the latest tracked year.
Wyeth's IL-12 adjuvant filings remain the most-cited anchor
Wyeth's interleukin-12 adjuvant work, including the representative 2008 filing, sits among the most-cited records in the corpus despite no recent-year filing activity, meaning its claim scope still shapes freedom-to-operate analysis for adjuvant formulation work today.
A research-institute filer with a co-assignee pairing
Jiangsu Academy of Agricultural Sciences appears in a co-assignee pair with Nanjing Guochuang Biotechnology Research Institute, one of four co-assignee relationships in the dataset, but shows no filings in the most recent tracked year.
The strongest co-assignee link in the dataset
Oswaldo Cruz Foundation and FABP Biotech Desenvolvimento em Biotecnologia jointly appear on 5 records, the largest co-assignee pairing found, though neither shows filings in the latest tracked year.
| Assignee | Recent year | YoY |
|---|---|---|
| Wyeth | 0 | — |
| Jiangsu Academy of Agricultural Sciences | 0 | — |
| Engineering Immunity Co., Ltd. | 0 | — |
| Center for Genetic Engineering and Biotechnology | 0 | — |
| Bunge (Australia) Pty Ltd | 0 | — |
| Oswaldo Cruz Foundation | 0 | — |
| FABP BIOTECH DESENVOLVIMENTO EM BIOTECNOLOGIA LTDA | 0 | — |
| Jinyu Baoling Biopharmaceutical Co., Ltd. | 0 | -100% |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio benchmarking or identifying open claim space.
Map freedom-to-operate around adjuvant claims
Cytokine-adjuvant and nanoparticle-formulation claims carry the heaviest citation weight in this corpus; a targeted search around those specific mechanisms will surface the blocking art faster than a broad keyword scan.
Explore adjuvant claim scope in EurekaTrack the China filing shift
With China now the largest single receiving office in this space, benchmarking Chinese-origin filings against the established Western prior art base clarifies where new entrants are building versus where they may be exposed.
Compare filing geography in EurekaTest claims in under-claimed branches
Peptide-subunit, polysaccharide-conjugate and DIVA-marker constructs show thin filing density relative to core formulation claims, making them worth a focused novelty check before committing R&D spend.
Run a white-space search in EurekaCommon questions on veterinary vaccine patents
This dataset tracks 114 patent families published between 2015 and mid-2026 that combine veterinary vaccine or animal biologics language with adjuvant, mass-administration, cold-chain, cross-protection or DIVA claim features. Filing activity rose steadily through the late 2010s, peaked at 21 families in 2023, and has since eased off. Because publication typically lags filing by around 18 months, the 2025-2026 figures understate true filing volume for those years.
China leads with 31 records in this corpus, followed by the European Patent Office with 20, the WIPO/PCT route with 14, the United States with 13, Canada with 7 and Australia with 6. That ordering shows the jurisdictional centre of new filing activity has moved toward China, even though several of the most-cited foundational patents in the field originate from US and European filers such as Wyeth.
DIVA stands for Differentiating Infected from Vaccinated Animals, a design requirement that lets diagnostic testing tell whether an animal's antibodies came from natural infection or from vaccination. It matters for disease-surveillance programmes and export certification, so claims referencing DIVA capability typically involve marker-gene deletion, subunit antigens or companion diagnostic assays alongside the vaccine formulation itself. It is one of the search terms used to build this dataset precisely because it signals a field-deployment-ready design rather than a lab-stage antigen.
Within this corpus, Wyeth's interleukin-12 adjuvant filings are among the most-cited records, appearing twice in the top five most-cited list under related filing numbers. An inactivated canine coronavirus vaccine patent is the single most-cited record overall, and nanoparticle-based and Salmonella-targeted vaccine compositions also rank highly. Citation counts reward older, longer-available filings, so these figures indicate historical influence on the field rather than current commercial dominance.
The IPC composition shows claim density concentrated almost entirely in A61K medicinal-preparation and A61P therapeutic-activity subclasses, which together cover nearly every record in the dataset. Peptide and protein claims (C07K), microorganism and genetic-engineering claims (C12N), fermentation-based production (C12P), polysaccharide derivatives (C08B) and nanotechnology applications (B82Y) each appear in single digits to low double digits, suggesting these adjacent branches carry lighter claim density relative to core formulation and adjuvant work. That does not guarantee an easy filing, but it does mean less prior art to design around.
Research Veterinary Vaccines and Biologics in depth with Eureka
Go past this page: query the whole veterinary vaccines and biologics corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.